$BLCO News

Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcript

Evercore ISI Group Maintains In-Line on Bausch & Lomb, Lowers Price Target to $16

Bausch + Lomb Corporation (BLCO) Q1 2026 Earnings Call Transcript

Bausch + Lomb Corp (NYSE:BLCO) Beats Q1 Estimates, Raises Full-Year Guidance

Bausch & Lomb Raises FY2026 Sales Guidance from $5.375B-$5.475B to $5.420B-$5.520B vs $5.436B Est

Bausch + Lomb Corporation 2026 Q1 - Results - Earnings Call Presentation

Bausch & Lomb Q1 Adj. EPS $0.08 Beats $0.06 Estimate, Sales $1.244B Beat $1.218B Estimate

Bausch + Lomb Receives FDA 510(k) Clearance For Bi-Blade+ Advanced Dual-Port Vitrectomy Cutter And Adaptive Fluidics Advanced Update On Stellaris Elite Vision Enhancement System

Evercore ISI Group Maintains In-Line on Bausch & Lomb, Lowers Price Target to $17

A Look At Bausch + Lomb (BLCO) Valuation After Recent Share Price Pullback

Bausch + Lomb Spotlights BL 1107 Eye Drop and ELIOS Implant-Free Laser as Glaucoma Catalysts

3 Reasons BLCO is Risky and 1 Stock to Buy Instead

A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday

Bausch + Lomb Higher in New York Trading, Reports Positive Elios Trial Results

Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma

Bausch + Lomb Announces 24-Month Results From Pivotal US Trial of ELIOS System For Elevated Intraocular Pressure In Open Angle Glaucoma Patients, Meeting Primary Effectiveness Endpoints

Is It Time To Reconsider Bausch + Lomb (BLCO) After Recent Share Price Weakness

Billboard Giant Posts $1.6 Billion Revenue as $20.5 Million Bet Makes It a Top Portfolio Holding

Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position